Go to content
UR Home

Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1

Haag, G.M. ; Zoernig, I. ; Hassel, J.C. ; Halama, N. ; Dick, J. ; Lang, N. ; Podola, L. ; Funk, J. ; Ziegelmeier, C. ; Juenger, S. ; Bucur, M. ; Umansky, L. ; Falk, C.S. ; Freitag, A. ; Karapanagiotou-Schenkel, I. ; Beckhove, P. ; Enk, A. ; Jaeger, D.


Background: Immune checkpoint therapy has dramatically changed treatment options in patients with metastatic melanoma. However, a relevant part of patients still does not respond to treatment. Data regarding the prognostic or predictive significance of preexisting immune responses against tumour antigens are conflicting. Retrospective data suggested a higher clinical benefit of ipilimumab in ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons